SCHEMBL306227

SCHEMBL306227

Cc1cc(C(=O)N2CCN(c3ccccc3)CC2)ccc1N(Cc1ccccc1)S(=O)(=O)c1cn(C)cn1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
REV1 Q9UBZ9 1/20 0.45
ALOX15 P16050 1/20 0.43
MAPT P10636 2/20 0.42
MAPK1 P28482 2/20 0.41
GAA P10253 1/20 0.41
TP53 P04637 1/20 0.41
USP2 O75604 1/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722793 0.91 LMNA (0.47) TSHRALDH1A1LMNASMN1; SMN2HTT
SCHEMBL1722406 0.87 LMNA (0.58) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL303115 0.85 LMNA (0.52) TSHRALDH1A1LMNASMN1; SMN2HTT
SCHEMBL1723243 0.84 LMNA (0.54) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL1725046 0.81 LMNA (0.54) TSHRLMNASMN1; SMN2HTTMEN1
SCHEMBL1725647 0.80 LMNA (0.53) ALDH1A1LMNASMN1; SMN2HTTMEN1
SCHEMBL303692 0.79 LMNA (0.66) ALDH1A1LMNASMN1; SMN2HTTMEN1
SCHEMBL303614 0.78 HTR2C (0.58) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL3275527 0.77 LMNA (0.51) TSHRALDH1A1LMNASMN1; SMN2HTT
SCHEMBL3376397 0.76 KMT2A (0.50) TSHRALDH1A1LMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 TSHR 1166/4885ALDH1A1 1588/4885LMNA 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.